http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2015106714-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2013-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2015106714-A |
| titleOfInvention | FORECASTING RESPONSE TO TREATMENT WITH JAK / STAT INHIBITOR |
| abstract | 1. A method of selecting an individual with a hematological malignant tumor for treatment with a JAK / STAT inhibitor, comprising determining the level of mRNA expression of at least two or more biomarkers shown in Table 1 in a biological sample taken from an individual in order to predict an increased likelihood of a response to a JAK / STAT inhibitor. 2. The method of claim 1, comprising determining the expression level of any three biomarkers from table 1.3. The method according to claim 1, including determining the level of expression of any four biomarkers from table 1.4. The method of claim 3, wherein the biomarkers include ΡΙΜ1, CISH SOCS2, and ID1.5. The method according to claim 1, including determining the level of expression of any six biomarkers from table 1.6. The method of claim 5, wherein the at least six biomarkers include ΡΙΜ1, CISH, SOCS2, ID1, LCN2, and EPOR. The method of claim 1, comprising determining an expression level of ΡΙΜ1, CISH, SOCS2, ID1, LCN2, EPOR, and EGR1.8. The method of claim 1, wherein the JAK / STAT inhibitor is (R) -3-cyclopentyl-3- [4- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1- sludge] propannitrile; or a pharmaceutically acceptable salt thereof. 9. The method of claim 1, wherein the hematologic malignant tumor is leukemia, lymphoma, or myeloma. A method of selecting an individual with a hematologic malignant tumor for treatment with a JAK / STAT inhibitor, wherein the method includes liboselectively administering a therapeutically effective amount of a JAK / STAT inhibitor to a patient selected based on the determination of an increased level of mRNA expression of two or more biomarkers shown in Table 1; liboselectively administering a therapeutically effective amount of an inhibitor that is not a JAK / STAT inhibitor to an individual selected based on the fact that the sample does not contain an increased level of mRNA expression of one or more biomarkers, |
| priorityDate | 2012-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 46.